Positive clinical results for liver cirrhosis
EnteroBiotix has announced positive results from its Phase Ib IMPuLCE study evaluating EBX-102 in patients with liver cirrhosis. EnteroBiotix’s first-in-human study of EBX-102 was a randomised, double-blind, placebo-controlled Phase Ib study of adult participants with stable liver cirrhosis. It was designed to evaluate the safety, tolerability, and… Read More